Human tissue intended for transplantation--FDA. Interim rule; opportunity for public comment.
The Food and Drug Administration (FDA) is issuing an interim rule to require certain infectious disease testing, donor screening, and recordkeeping to help prevent the transmission of AIDS and hepatitis through human tissue used in transplantation. The regulations are effective upon publication. FDA is taking this action in response to growing concerns that some human tissue products are being offered for transplantation use without even the minimum donor testing and screening needed to protect recipients against human immunodeficiency virus (HIV) infection and hepatitis infection. The new regulations require all facilities engaged in procurement, processing, storage, or distribution of human tissues intended for transplant to ensure that minimum required infectious disease testing has been performed and that records documenting such testing for each tissue are available for inspection by FDA. The regulations also provide authority for the agency to conduct inspections of such facilities and to detain, recall, or destroy tissue for which appropriate documentation is not available.
D017848:Blood-Borne Pathogens; D003140:Communicable Disease Control / Q000331:legislation & jurisprudence*; D004282:Documentation / Q000592:standards; D015658:HIV Infections / Q000517:prevention & control; D006505:Hepatitis / Q000517:prevention & control; D006801:Humans; D014015:Tissue Banks / Q000331:legislation & jurisprudence* / Q000458:organization & administration; D009927:Tissue and Organ Procurement / Q000331:legislation & jurisprudence; D014481:United States; D014486:United States Food and Drug Administration